Passage Bio Inc (NAS:PASG)
$ 0.657 -0.0029 (-0.44%) Market Cap: 40.58 Mil Enterprise Value: -18.43 Mil PE Ratio: 0 PB Ratio: 0.56 GF Score: 36/100

Passage Bio Inc at Chardan Genetic Medicines Conference Transcript

Oct 02, 2023 / 09:00PM GMT
Release Date Price: $0.659 (+0.15%)
Geulah Livshits
Chardan Capital Markets, LLC - Analyst

(audio in progress) noon. It is now my pleasure to introduce our next guest, Dr. William Chou, President and CEO of Passage Bio. And the format for this is a fireside chat. So thank you for joining us today.

Questions & Answers

Geulah Livshits
Chardan Capital Markets, LLC - Analyst

To start with, can you give us a high-level overview of Passage Bio and highlight any upcoming catalysts?

William Chou
Passage Bio, Inc. - President & CEO

Be happy to. Thank you for having us. So we are an AAV gene therapy company focused on CNS disease. We do have a major catalyst coming up at the end of the year. This will be the first time we have shared clinical data from one of our gene therapy programs in frontotemporal dementia in patients with a granulin mutation.

We have two clinical-stage programs. One is in GM1 gangliosidosis, and the other one is in FTD. So we're pretty excited by what we're seeing out of the FTD trial. And we're excited to share

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot